Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.39 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 9/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941284 | 1.00 | FOLH1 (0.42) | FOLH1SRRPSAT1MMECHRM1 | |
| SCHEMBL14890861 | 0.90 | MME (0.47) | MMEACE | |
| SCHEMBL19190551 | 0.90 | MME (0.47) | MMEACE | |
| SCHEMBL18724735 | 0.82 | MME (0.46) | MMEACE | |
| SCHEMBL17011152 | 0.82 | MME (0.46) | MMEACE | |
| SCHEMBL9929533 | 0.81 | MME (0.53) | SRRPSAT1MMEGPR88ACE | |
| SCHEMBL9966297 | 0.81 | MME (0.53) | SRRPSAT1MMEGPR88ACE | |
| SCHEMBL9929512 | 0.81 | MME (0.53) | SRRPSAT1MMEGPR88ACE | |
| SCHEMBL9929510 | 0.81 | MME (0.53) | SRRPSAT1MMEGPR88ACE | |
| SCHEMBL9929634 | 0.81 | MME (0.53) | SRRPSAT1MMEGPR88ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10336773-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9845332-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9388145-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160016918-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-9120747-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2651896-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8586536-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | FOLH1 4709/4885SRR 2806/4885PSAT1 3904/4885 |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-10336773-B2 | Neprilysin inhibitors | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20160016918-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FOLH1 1087/4885SRR 114/4885PSAT1 3704/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | FOLH1 1095/4885SRR 112/4885PSAT1 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.